Glucose metabolism disorders associated with COVID-19: clinical and morphological study

BACKGROUND. Glucose metabolism disorders (GMD) were detected both in acute and in post-COVID, however, its pathogenic aspects remain unclear.

AIM. To analyze the occurrence of GMD in post-COVID patients who have had moderate and severe COVID-19 without previously known GMD disorders, and evaluate expression of SARS-CoV-2 proteins and its entry factors in pancreas in acute COVID-19.

METHODS. Among 187 hospitalized patients with confirmed COVID-19 141 patients without previously diagnosed GMD underwent follow-up post-COVID visits. The examination for all patients included anthropometric measurement with calculation of BMI, level of HbA1c and fasting plasma glucose, for 106 patients level of insulin and HOMA-IR index was analyzed. For histological examination, pancreas fragments of 20 patients with fatal outcome were selected. Immunohistochemical study was performed with antibodies to SARS-CoV-2, ACE2, DPP4, as well as double-labeled immunofluorescence microscopy (insulin-SARS-CoV-2, insulin-ACE2, insulin-DPP4).

RESULTS. Among 141 patients in post-COVID period, 9 (6.3%) had HbA1c or fasting plasma glucose levels that met criteria for diabetes mellitus, 38 (26.9%) — exceeded normal values (WHO), and 84 (59.6%) had GMD according to criteria of the ADA. In post-COVID, patients with GMD had a higher BMI and HOMA-IR index (p=0.001) compared to patients with normal glycemic levels. Only 40.4% of people had HOMA-IR index above 2.7. Patients with GMD had higher level of CRP (p=0.007) and a maximum glucose level (p=0.019) in the acute period. Positive relationship was found between BMI and HOMA index both in acute (p<0.001; r=0.389) and post-COVID (p<0.001; r=0.412) periods, as well as the level of HbA1c in acute period (p=0.019, r=0.202) and in post-COVID (p=0.004, r=0.242).

Histological and immunohistochemical studies showed the expression of SARS-CoV-2 proteins in 1.85% [0–15.4] and 11.1% [5.3–14.8] cells of the Langerhans islets in patients who died on the second and third waves, respectively. The expression of ACE2 and DPP4 in the islets of Langerhans did not exceed 0.4% [0–1.7] and 0.5% [0–0.8] of cells, respectively. Double-labeled immunofluorescence microscopy showed co-localization of SARS-CoV-2, ACE2, DPP4 with insulin.

CONCLUSION. Post-COVID Glucose metabolism disorders may be explained by direct cytotoxic effect of SARS-COV-2, increased glucose toxicity and insulin resistance because of the acute infection and its complex therapy.

1. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-544. doi: https://doi.org/10.1038/s41564-020-0695-z

2. Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the Endocrine System: A Mini-review. Endocrinology. 2022;163(1):bqab203. doi: https://doi.org/10.1210/endocr/bqab203

3. Mirza SA, Sheikh AAE, Barbera M, et al. COVID-19 and the endocrine system: A review of the current information and misinformation. Infect Dis Rep. 2022;14(2):184-197. doi: https://doi.org/10.3390/idr14020023

4. Millette K, Cuala J, Wang P, et al. SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction. Preprint. Res Sq. 2021;rs.3.rs-592374. doi: https://doi.org/10.21203/rs.3.rs-592374/v1

5. Coate KC, Cha J, Shrestha S, et al. SARS-CoV-2 Cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metab. 2020;32(6):1028-1040.e4. doi: https://doi.org/10.1016/j.cmet.2020.11.006

6. Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125-136.e7. doi: https://doi.org/10.1016/j.stem.2020.06.015

7. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-199. doi: https://doi.org/10.1007/s00592-009-0109-4

8. Liu F, Long X, Zhang B, et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(9):2128-2130.e2. doi: https://doi.org/10.1016/j.cgh.2020.04.040

9. Fignani D, Licata G, Brusco N, et al. SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-Cells and in the human pancreas microvasculature. Front Endocrinol (Lausanne). 2020;(11). doi: https://doi.org/10.3389/fendo.2020.596898

10. Coate KC, Cha J, Shrestha S, et al. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metab. 2020;32(6):1028-1040.e4. doi: https://doi.org/10.1016/j.cmet.2020.11.006

11. Steenblock C, Richter S, Berger I, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021;12(1):3534. doi: https://doi.org/10.1038/s41467-021-23886-3

12. Cure E, Cumhur Cure M. COVID-19 may affect the endocrine pancreas by activating Na+/H+exchanger 2 and increasing lactate levels. J Endocrinol Invest. 2020;43(8):1167-1168. doi: https://doi.org/10.1007/s40618-020-01307-4

13. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-294. doi: https://doi.org/10.1080/713609354

14. Drucker DJ. Coronavirus infections and type 2 diabetesshared pathways with therapeutic implications. Endocr Rev. 2020;41(3):bnaa011. doi: https://doi.org/10.1210/endrev/bnaa011

15. Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. N Engl J Med. 2020;383(8):789-790. doi: https://doi.org/10.1056/NEJMc2018688

16. Rey-Reñones C, Martinez-Torres S, Martín-Luján FM, et al. Type 2 diabetes mellitus and COVID-19: A narrative review. Biomedicines. 2022;10(9):2089. doi: https://doi.org/10.3390/biomedicines10092089

17. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-634. doi: https://doi.org/10.1016/j.pcd.2021.04.004

18. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. doi: https://doi.org/10.1016/S0140-6736(20)32656-8

19. Zhang T, Mei Q, Zhang Z, et al. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med. 2022;20(1):444. doi: https://doi.org/10.1186/s12916-022-02656-y

20. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022;65(6):949-954. doi: https://doi.org/10.1007/s00125-022-05670-0

21. Shestakova M, Kononenko I, Kalmykovа Z, et al. Glycated hemoglobin level dynamics in COVID-19 survivors: 12 months follow-up study after discharge from hospital. PLoS One. 2022;17(11):e0275381. doi: https://doi.org/10.1371/journal.pone.0275381

22. Millette K, Cuala J, Wang P, Marks C, et al. SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction. Preprint. Res Sq. 2021:rs.3.rs-592374. doi: https://doi.org/10.21203/rs.3.rs-592374/v1

23. Geravandi S, Mahmoudi-Aznaveh A, Azizi Z, et al. SARS-CoV-2 and pancreas: a potential pathological interaction? Trends Endocrinol Metab. 2021;32(11):842-845. doi: https://doi.org/10.1016/j.tem.2021.07.004

24. Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021;33(8):1565-1576. e5. doi: https://doi.org/10.1016/j.cmet.2021.05.013

25. Keerthi BY, Sushmita G, Khan EA, et al. New onset diabetes mellitus in post-COVID-19 patients. J Family Med Prim Care. 2022;11(10):5961-5968. doi: https://doi.org/10.4103/jfmpc.jfmpc_316

26. Montefusco L, Ben Nasr M, D’Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774-785. doi: https://doi.org/10.1038/s42255-021-00407-6